Abstract
Abstract Venetoclax, a BCL2 inhibitor, has been approved for patients with chronic lymphocytic leukemia (CLL) who lack part of chromosome 17. The FDA also approved a companion diagnostic, the Vysis CLL FISH probe kit, to detect the 17p deletion in patients' peripheral blood.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
